source
- Replimune seeks third FDA approval attempt, Pfizer signs China deal, panel backs updated Covid vaccineReplimune is pursuing a third attempt to secure FDA approval for its investigational therapy, after two prior submissions did not succeed. Pfizer has entered into a new agreement to expand its pre…
- Allogene announces CEO David Chang will step downAllogene Therapeutics disclosed that its chief executive, David Chang, will be leaving the company. The firm indicated that a succession plan is in place, though it did not provide a specific timel…